Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate

Front Bioeng Biotechnol. 2023 Jan 26:11:1108300. doi: 10.3389/fbioe.2023.1108300. eCollection 2023.

Abstract

Streptococcus pneumoniae is a bacterial pathogen exclusive to humans, responsible for respiratory and systemic diseases. Pneumococcal protein vaccines have been proposed as serotype-independent alternatives to currently used conjugated polysaccharide vaccines, which have presented limitations regarding their coverage. Previously in our group, pneumococcal surface protein A (PspA) and detoxified pneumolysin (PdT) were genetically fused and the hybrid protein protected mice against pneumococcal challenge, offered higher cross-protection against different strains and showed greater opsonophagocytosis rate than co-administered proteins. As juxtaposed fusion was unstable to upscale production of the protein, flexible (PspA-FL-PdT) and rigid (PspA-RL-PdT) molecular linkers were inserted between the antigens to increase stability. This work aimed to produce recombinant fusion proteins, evaluate their stability after linker insertion, both in silico and experimentally, and enable the production of two antigens in a single process. The two constructs with linkers were cloned into Escherichia coli and hybrid proteins were purified using chromatography; purity was evaluated by SDS-PAGE and stability by Western blot and high performance size exclusion chromatography. PspA-FL-PdT showed higher stability at -20°C and 4°C, without additional preservatives. In silico analyses also showed differences regarding stability of the fusion proteins, with molecule without linker presenting disallowed amino acid positions in Ramachandran plot and PspA-FL-PdT showing the best scores, in agreement with experimental results. Mice were immunized with three doses and different amounts of each protein. Both fusion proteins protected all groups of mice against intranasal lethal challenge. The results show the importance of hybrid protein structure on the stability of the products, which is essential for a successful bioprocess development.

Keywords: PspA; Streptococcus pneumoniae; mouse immunization; pneumolysin; protease detection; protein structural model; recombinant Escherichia coli; spacer.

Grants and funding

This research was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP grant numbers 2017/24832-6 and 2016/50413-8, and Fundação Butantan. VA, MT and CG received scholarship from FAPESP, grant numbers 2021/02930-1, 2019/06454-0, and 2009/17030-4, respectively. LZ received scholarships from Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq grant number 130373/2018-4, and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES grant number 88887.465206/2019-00. SK received scholarship from CAPES.